Home
About
Science
- ALS
- Parkinson’s Disease
Mitometin
- Pipeline
News
Investors
Publications
Contact

Home
About
Science
- ALS
- Parkinson’s Disease
Mitometin
- Pipeline
News
Investors
Publications
Contact

2N Pharma wins Servier Golden Ticket

At the Servier Partnering Day in Malmö, Sweden on 21 May 2025, 2N Pharma won the Servier Golden Ticket.

2npharma

2N Pharma is a small biotech company with a big vision: we want to cure ALS and other currently incurable neurodegenerative diseases.

We are thrilled with today's publication of an art

We are thrilled with today's publication of an article (in Danish) in Dansk Biotek and BusinessReview in which we discuss our innovative approach to treating #parkinsonsdisease and #ALS. Read full text here: https://lnkd.in/ejqXRqeR

Today marks the third anniversary of 2N Pharma. We

Today marks the third anniversary of 2N Pharma. We would like to thank our collaboration partners as well as our employees. #drugdevelopment #ALS #Parkinson #valentineday

New article! 💙 (See link in bio) The results

New article! 💙 (See link in bio)

The results show that in mice with symptoms resembling Parkinson's disease, modulating cellular energy generation can restore both their motor and non-motor functions. Both toxicity-induced and genetic mouse models of Parkinson's disease were used to investigate this.

Congratulations to Dr Michael Sloth Trabjerg MD, 2N Pharma Co-Founder, CSO and Aalborg University Associate Professor Dr John Dirk Vestergaard Nieland, and collaborators on the publication of their newest article in npj Parkinson’s Disease.

#article #newarticle #parkinson #parkinsonsdisease #biotech #testing #cellularenergy #parkinsonsdiseaseawareness
#brainhealth #braindisease #newmedicine #turnhopeintoreality #2npharma #mentalhealth #pharma #lifesciences #research #alsawareness #dementia #als #denmark #Aalborg #Nordjylland

Do you want to learn more about the new medicines

Do you want to learn more about the new medicines being developed by 2N Pharma, and the results we have achieved?

Do you have any questions as a patient or relative about what you can do to improve your situation?

👉 Then save the date on April 26, 2023!

Co-founder and CSO Dr. John Vestergaard Nieland, has, in collaboration with his research team, made breakthroughs in the development of new medicines to help improve the life expediency of Parkinson’s, Multiple Sclerosis and Alzheimer’s patients.

In the lecture, John, will discuss how it all fits together. What we have tested for, and how we test it.

Read more and sign up for the lecture at fuaalborg.dk - "Ny forskning om hjernens sygdomme - Parkinsons sygdom, Multiple Sklerose og Alzheimer"

NB – this lecture is in Danish.

#lecture #aalborguniversity #aalborguniversitet #brainhealth #braindisease #newmedicine #turnhopeintoreality #2npharma #mentalhealth #pharma #lifesciences #research #alsawareness #parkinsonsdisease #dementia #als #denmark #Aalborg #Nordjylland

Load More... Follow on Instagram

LinkedIn
Twitter

About
Technology
Pipeline
News
Investors
Publications
Contact

Policies, Terms & Conditions
Website Terms and Conditions
Data Privacy Policy
Cookie Policy
GDPR Compliance

2N Pharma ApS
Novi Science Park, Niels Jernes Vej 10, 9220 Aalborg Ø, Denmark
BioInnovation Institute, Ole Maaløes Vej 3, 2200 København N, Denmark
CVR: 41169303 VAT: DK41169303 D-U-N-S: 306192737
email: info@2npharma.com

Twitter feed is not available at the moment.